https://www.selleckchem.com/pr....oducts/triparanol-me
enefit from estrogen withdrawal therapy via aromatase inhibition, as opposed to ER modulation/antagonism. Our data confirms previous reports that anti-estrogens induce an adverse cell phenotype in ER+ breast cancer, particularly in the absence of homotypic cell contact. These results implicate E-cadherin and PELP-1 as potential biomarkers when deciding upon optimum adjuvant endocrine therapy, whereby tumours with high PELP-1/low E-cadherin expression may benefit from estrogen withdrawal therapy via aromatase inhibition, as opp
Curtir
Comentario
Compartilhar
